Literature DB >> 9462926

Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates.

S Palmer1, A Alaeus, J Albert, S Cox.   

Abstract

We determined the susceptibility to antiviral drugs of clinical isolates of human immunodeficiency virus type 1 (HIV-1) subtypes A, B, C, D, and E. Isolates from treated and untreated patients were tested for sensitivity to zidovudine (ZDV), lamivudine (3TC), didanosine (ddI), nevirapine (NVP), foscarnet (PFA), and ritonavir (RNV). The susceptibility to these different drugs was broadly similar between the different subtypes of HIV-1. Isolates of subtype D showed a tendency toward slightly lower susceptibility to all the antiviral drugs, which could be related to the rapid growth characteristics of these isolates.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9462926     DOI： 10.1089/aid.1998.14.157

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN： 0889-2229            Impact factor:   2.205


  22 in total

1.  Prevalence of different HIV-1 subtypes in an urban clinic in Madrid.

Authors:  J C Martín; A Holguín; V Soriano
Journal:  Sex Transm Infect       Date:  2002-02       Impact factor: 3.519

2.  In vivo toxicity, pharmacokinetics, and anti-human immunodeficiency virus activity of stavudine-5'-(p-bromophenyl methoxyalaninyl phosphate) (stampidine) in mice.

Authors:  Fatih M Uckun; Sanjive Qazi; Sharon Pendergrass; Elizabeth Lisowski; Barbara Waurzyniak; Chun-Lin Chen; T K Venkatachalam
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

3.  Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes.

Authors:  A Velazquez-Campoy; M J Todd; S Vega; E Freire
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

4.  A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Authors:  Robert W Shafer; Kathryn Dupnik; Mark A Winters; Susan H Eshleman
Journal:  HIV Seq Compend       Date:  2001

5.  Prevalence of human immunodeficiency virus type 1 (HIV-1) non-B subtypes in foreigners living in Madrid, Spain, and comparison of the performances of the AMPLICOR HIV-1 MONITOR version 1.0 and the new automated version 1.5.

Authors:  A Holguín; B Aracil; A Alvarez; C Barros; V Soriano
Journal:  J Clin Microbiol       Date:  2001-05       Impact factor: 5.948

6.  Human immunodeficiency virus type 1 group m protease in cameroon: genetic diversity and protease inhibitor mutational features.

Authors:  Peter N Fonjungo; Eitel N Mpoudi; Judith N Torimiro; George A Alemnji; Laura T Eno; Esther J Lyonga; John N Nkengasong; Renu B Lal; Mark Rayfield; Marcia L Kalish; Thomas M Folks; Danuta Pieniazek
Journal:  J Clin Microbiol       Date:  2002-03       Impact factor: 5.948

7.  Determination of human immunodeficiency virus type 1 subtypes in Taiwan by vpu gene analysis.

Authors:  C N Lee; W K Wang; W S Fan; S J Twu; S C Chen; M C Sheng; M Y Chen
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

8.  Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus type 1 found in Brazilian patients failing HAART.

Authors:  E Caride; K Hertogs; B Larder; P Dehertogh; R Brindeiro; E Machado; C A de Sá; W A Eyer-Silva; F S Sion; L F Passioni; J A Menezes; A R Calazans; A Tanuri
Journal:  Virus Genes       Date:  2001       Impact factor: 2.332

9.  High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis.

Authors:  Emanuele Nicastri; Loredana Sarmati; Gabriella d'Ettorre; Saverio G Parisi; Lucia Palmisano; Clementina Galluzzo; Marco Montano; Ilaria Uccella; Roberta Amici; Francesca Gatti; Vincenzo Vullo; Ercole Concia; Stefano Vella; Massimo Andreoni
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

10.  Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistance.

Authors:  Krista A Delviks-Frankenberry; Renan B Lengruber; Andre F Santos; Jussara M Silveira; Marcelo A Soares; Mary F Kearney; Frank Maldarelli; Vinay K Pathak
Journal:  Virology       Date:  2012-10-13       Impact factor: 3.616
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.